PTPRC and neoplasm: Overall, MPE had the highest percentage of CD45+ immune cells (94.8% in MPE vs. 89.8% in blood vs. 14.7% in tumor; Figure S5) and CD3+ T cells (74.9% in MPE vs. 58.6% in tumor vs. 48.7% in blood; Figure 1B).